FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with ...

Intraocular lenses (IOLs), implanted in the eye as treatment for cataracts or myopia, are a growing global market in an ageing population, one estimated to be worth more than $4.5 billion by 2022.

First Preloaded Toric Available in the United States and Monofocal Option Combine Consistent IOL Delivery with Outstanding Visual Outcomes of enVista® LAVAL, QC, Oct. 27, 2020 /PRNewswire/ -- Bausch + ...

PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses 1,2 More than ninety-nine percent of PanOptix patients in the FDA ...

Celebrating 75 years of intraocular lens advancements that have improved care for millions of cataract patients. On November 29, 1949, Sir Harold Ridley performed a surgical procedure to replace a ...

Cataract surgery is a once-in-a-lifetime investment in your eyes that can improve your quality of life for the long term. Advanced lens options can reduce or eliminate the need for glasses after your ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

NEW YORK, Oct. 12, 2017 /PRNewswire/ -- Intraocular Lens (IOL) - Medical Devices Pipeline Assessment, 2017 Summary GlobalData's Medical Devices sector report, "Intraocular Lens (IOL) - Medical Devices ...

Medical Disclaimer: This article is provided for general information and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek advice from a qualified ...

The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release ...